$ZTNE #RKTZzPost The Next Equity #Rocketz – Format $xxxx
Subscribe to the thread to receive e-mail(s) on The $NEXT #RKTZ.
Discuss Equity; Your DD – Due Diligence
Zest2U4U-Jammin’
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
$CAPR -It’s rocket science!
$LWLG – Lightwave Logic Achieves Polymer-Based Mach-Zehnder Modulators with 50GHz Operation, Opening the Door for 400Gbps Modulation in Fiber Optic Communications
http://www.globenewswire.com/news-release/2017/09/19/1124803/0/en/Lightwave-Logic-Achieves-Polymer-Based-Mach-Zehnder-Modulators-with-50GHz-Operation-Opening-the-Door-for-400Gbps-Modulation-in-Fiber-Optic-Communications.html
Lightwave Logic’s CEO Dr. Michael Lebby will announce the results during his presentation at the prestigious ECOC meeting on September 20, 2017, in Gothenburg, Sweden
Longmont, Colorado, Sept. 19, 2017 (GLOBE NEWSWIRE) — Lightwave Logic, Inc. (OTCQB: LWLG), a technology company focused on the development of Next Generation Photonic Devices and Non-Linear Optical Polymer Materials Systems for applications in high-speed fiber-optic data communications and telecommunications with advanced photonic integrated circuit (PIC) platforms, announced today that Lightwave Logic has achieved outstanding performance of its ridge waveguide Mach-Zehnder modulators ahead of schedule, with bandwidth performance levels that will enable 50Gbps modulation in fiber-optic communications….
It’s been a long wait since this 2017 article but Lightwaye Logic, LWLG, is making waves this week and Wednesday Sep 1st, 2021 the company will move from the OTC to NASDAQ – acquiring a new respectability in the process. Many positive developments in their field of using polymers in photonic application for very high speed data transfers. The technology and lingo are beyond me but the years of development and the people behind the technology seem very solid and this has potential for upending an entire field. Proponents are calling it disruptive. Opening bell Wednesday we’ll see how a whole new cadre of investors, ETFs, Funds and analysts view and greet NASDAQ’s newest member.
Current transfer speeds are well above the 50 GHz cited in the 2017 item above and Dr. Lebby will be presenting at the 2021 ECOC meeting in a couple of weeks with news that they have now achieved 400Gbps. The NASDAQ membership is only part of several announcements expected this fall from Lightwave. The stocks final closing price on the OTC today was 11.23. They will trade under the same symbol, LWLG, tomorrow on the NASDAQ exchange.
$ECYT – in at 4.89 for a trade
$ECYT – its already at 5,70 way to go .
$VICL same but lower float NO position only one at a time for me. IF data is GOOD….I did not DD
$ECYT out at 5.45
$ECYT np – Seems I got out too soon Samuel. Had no time to DD and watch, plus I’m slow, as care giving is my priority. I’m only human. 🙂 and TIB 🙂 Best2You
Bless you care giver!
Sogi
How do you buy in pre market TD Ameritrade doesn’t work
Also have InteractiveBrokers.com account for Global trading, although seldom use. Shall probably open a Schwab account this month and move cash as I close positions ONE at a time.
Look at Message.. they changed schedule to full From: Notices|Date: 09/11/17 3:10 PMMessage available until 01/12/18.
We’re pleased to announce that starting September 21, 2017, we will be expanding our Extended-Hours Trading sessions. You’ll be able to trade during a continuous 13-hour trading session (Day + Ext. and GTC + Ext.) instead of 12.
Beginning on that date, the Day + Ext. and GTC + Ext. sessions will start an hour earlier, at 7 a.m. ET; the A.M.-only session will start an hour earlier, at 7 a.m. ET, and close at 9:28 a.m. ET instead of 9:15; and the P.M.-only session will start at 4:02 p.m. ET instead of 4:15.
All open orders within these sessions will be adjusted to align with the new times.
Here’s a quick summary of the expanded hours:
Session Current Start Current Finish New Start New Finish
AM Extended-Hours Trading Session 8 a.m. ET 9:15 a.m. ET 7 a.m. ET 9.28 a.m. ET
Regular Market Hours 9:30 a.m. ET 4 p.m. ET
PM Extended-Hours Trading Session 4:15 p.m. ET 8 p.m. ET 4:02 p.m. ET 8 p.m. ET
Day+Ext Session 7 a.m. ET 8 p.m. ET
This change will give you an extra hour to make investment decisions, take advantage of early morning news, factor in earnings announcements, and so on. It’s part of our continuing effort to improve your trading experience.
If you have any questions, please let us know. Just reply to this message to write us, or call Client Services at 800-669-3900. We’re available 24 hours a day, seven days a week.
Best2You and ALL Long #ZKSS, Sharing and Gummunity!
Thanks so much!!
You are welcome Gail. Please consider using Thumbs UP to say thanks as it last. Also, if you have any questions I am glad to assist, to the best of my ability. Best2YOU and ALL – Ben
S&P500 futures liquidity at highest level for this time of day in 2017 (today=black). $ES_F $SPY Short-term volatility killer
https://twitter.com/nanexllc/status/915518616778534913
Visualizing risk, return and time. https://twitter.com/daniel_egan/status/915185514252292096
$CAPR Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at #WMS2017 Longer at $ 3.70
https://twitter.com/odibro/status/915532840351289344
http://www.prnewswire.com/news-releases/capricor-therapeutics-presents-positive-six-month-results-in-duchenne-muscular-dystrophy-at-world-muscle-society-international-congress-300530703.html
Emerson, Lake & Palmer – Very Best Of (Full Album)
https://www.youtube.com/watch?v=37e6_hdVonk
#BestOfTheBest includes #FrankA #ZKSS 🙂
$VKTX Viking Therapeutics Announces ‘Positive’ Top-Line Results from Proof-of-Concept Study of VK0214
https://twitter.com/BlinkX90/status/915538906707300352
https://twitter.com/odibro/status/915533689135693824
$RGSE in – Appears to be breaking out further 😉
Initial news and start of DD: https://www.stockgumshoe.com/2017/10/microblog-ev-vehicles-october-02-17-beyond/comment-page-1/#comment-4953292
Huge news for $RGSE agreement with DOW Chemical Co for solar shingles
$RGSE IN – Webcast NOW – http://public.viavid.com/player/index.php?action=refresh&eid=126573&rid=537621
PowerHouse 3.0 posted images today https://rgspowerhouse.com/
Dow started installing panels in 2008; 2015 variety of arrangements; PowerHouse 3.0 installations begin 1Q2018
Exclusive license with DOW; now DOW representative speaking; RGS live up to their commitments.
8K filed with SEC today: http://investors.rgsenergy.com/node/10356/html
$RGSE up 40%+ in pre-market… October 11, 2017
12:33 pm ET
*RGS Energy Reports Has Been Selected By Solarize New Haven For Solar Electricity Homes, Business Owners In Connecticut, No Terms Disclosed
Benzinga 700K volume long
$RGSE – November 20, 2017 8:31 AM EST
RGS Energy Launches Solar 365™ to Further Drive Revenue Growth
http://investors.rgsenergy.com/news-releases/news-release-details/rgs-energy-launches-solar-365tm-further-drive-revenue-growth
$PTNUF long – Added at .082 See HendrixNuzzles thread: https://www.stockgumshoe.com/2017/02/microblog-scandium-cobalt-and-water-purification-cleanteq-holdings/comment-page-9/#comment-4953345
$BIOP In this a.m. Small Position See: EV>thread: https://www.stockgumshoe.com/2017/10/microblog-ev-vehicles-october-02-17-beyond/comment-page-1/#comment-4953310
MBOT In this a.m. – Price $1.32 Day’s Change 0.1299 (10.92%) See #AI Thread: https://www.stockgumshoe.com/2016/04/microblog-ai-artificial-intelligence/comment-page-2/#comment-4953290
$PTOTF & $ABEO – A Double Bagger and a Triple Bagger In the Books: http://www.smallcapnetwork.com/A-Double-Bagger-and-a-Triple-Bagger-In-the-Books-PTOTF-and-ABEO/s/article/view/p/mid/7/id/2414/
For $ABEO see: https://www.stockgumshoe.com/author/dr-kss-md-phd/
Long GREAT Gummunity – #Sharing&Caring #Best2ALL
$MBOT strong close above the EMA50 for the first time in 5 months.
https://twitter.com/ACInvestorBlog/status/915675970786529280
$PTNUF 2017 Annual Report available: https://www.stockgumshoe.com/2017/02/microblog-scandium-cobalt-and-water-purification-cleanteq-holdings/comment-page-9/#comment-4953354
#EnjoySailing as well #friend
… #Time4CoolChange https://www.youtube.com/watch?v=9bKwRW0l-Qk … @KSSMDPhD #biotech #ZKSS #FF
https://twitter.com/H0U3/status/915680301917114368
$ABIO See: https://www.stockgumshoe.com/author/dr-kss-md-phd/
$BIOP In this a.m. Small Position See: EV>thread: https://www.stockgumshoe.com/2017/10/microblog-ev-vehicles-october-02-17-beyond/comment-page-1/#comment-4953310
$BIOP long– October 11, 2017 2:28 pm ET
*Riot Blockchain 13G Filing From Jonathan Honig Shows 9.51% Stake
Benzinga October 11, 2017 1:00 pm ET
Bitcoin Cryptocurrency Price Back to Near All-time High
PR Newswire
$RIOT long – Up 31%
*Riot Blockchain Shares Up 16.61% On Nearly 10x Avg. Volume As Bitcoin Remains Strong Benzinga
Inseego Corp. – Common Stock
NASDAQ : $INSG Option Chain
$1.77 0.27 (18.00%)
Bid/Ask
1.66 / 1.75
B/A Size
100 X 100
Volume
14,504
$MZOR: Premarket Gainers as of 9:05 am includes $INSG now at $1.60 https://seekingalpha.com/news/3299951-premarket-gainers-9-05
IHUB Breakout Boards – $OCSY $RMTD $INCT $GGSM $ICTY $EPGL $DIGAF $GAHC $CYDY $ONCS $BDGN $UHLN $BTCS $RAD $CCTL
https://twitter.com/BigCheds/status/918810756560367616
Long $ DERM
Dermira reports results from ARIDO at the Fall Clinical Dermatology Conference (29.43)
Phase 3 ARIDO Study Outcomes
After an additional 44 weeks of treatment, 59.8% of patients (n=329) reported one or more TEAE, and most were considered mild or moderate in severity. The most frequently reported TEAEs observed in patients were dry mouth (16.9%; n=93), blurred vision (6.7%; n=37), application site pain (6.4%; n=35), the common cold (5.8%; n=32) and pupil dilation (5.3%; n=29). Prespecified anticholinergic TEAEs of interest, defined as those associated with a subset of anticholinergic side effects, were reported in 14.2% of patients (n=78) and most were mild or moderate in severity and were able to be managed by dose interruption. Serious TEAEs were reported in 1.3% of patients (n=7).
An efficacy assessment conducted at the end of the treatment period in ARIDO suggests that patients who received glycopyrronium tosylate and completed the 44-week follow-up period maintained reduced sweat production compared to baseline and reported less bothersome sweating compared to baseline measures in ATMOS-1 and ATMOS-2. Notably, mean sweat production decreased by 95.77 ±140.8 mg/5 min and 63.2% of patients had =2-grade improvement in the Hyperhidrosis Disease Severity Scale (HDSS).
$DERM.. admdr5.. So this treatment works by reducing overall body sweat? I’m sure my wife would like that, given her current menopausal state, but isn’t sweating one of the major ways the body cleans itself from the inside out? I envision a group of toxins all shouting “Woo-hoo” and throwing their hands up in the air because they (now) won’t be tossed out of the party. I haven’t looked into the drug, just trying to understand how it works.
$MARK sp – October 13, 2017 12:28 pm ET
Remark Holdings’ 3D Augmented Reality Chosen To Be Core Technology Behind Launch of Sina Weibo’s New Mobile Application PR Newswire
$MARK long – Up 27% Best2ALL!
#Premarket Top % Gainers: $CLSN 28%, $ARDX $PTNR $XNET $PANW $CMCM $URBN $LPL $AKS $TOUR $DGAZ $CYRN $LOW $BURL $CDE $STO $MRVL $BP $UWT $MU thx ace
#VIA Small Cap Traders this a.m.
Good day traders,
We wanted to bring you more information regarding Citius Pharmaceuticals, Inc. (NASDAQ: CTXR). Yesterday brought some modest 13.58% intra-day gains and closing up 11.4%, but today we want to talk about why CTXR is a “Must have” stock in the biopharma market space with extraordinary potential.
CTXR has two products with blockbuster potential, and the lead product is Mino-Lok™. We think that Mino-Lok™ is the product that could propel CTXR shares significantly upward, so we want to talk more about it.
Mino-Lok™ is a new approach to treating infected Central Venous Catheters (CVCs). Today physicians must remove an infected CVC and re-insert it in a different location. Mino-Lok™ contains a proprietary combination of drugs already approved by the FDA, minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, and provide anti-clotting properties to maintain patency in CVCs. Mino-Lok™ allows the CVC to remain in place and treats the infection, eliminating the need to remove and replace the infected CVC.
Mino-Lok™ was developed at the M.D. Anderson Cancer Center. Citius obtained a worldwide license to the patented technology and the patent runs until 2024.
In a Phase 2b trial, the Mino-Lok™ product demonstrated a 100% efficacy rate.
Citius is preparing a Phase 3, multi-center, randomized, double blind, placebo- and active- controlled study in 700 patients.
Mino-Lok™ has QIDP designation, meaning that it’s eligible for additional FDA incentives in the approval and marketing pathway, including Fast Track designation and Priority Review for development, and a five-year extension of market exclusivity.
Two weeks ago, Mino-Lok™ received Fast Track designation from the FDA.
CTXR had a third-party survey 31 doctors experienced with infected CVCs, and all agreed that the Mino-Lok™ treatment would be preferred over the current standard of removal and replacement.
In September, the FDA stated that they recognized there is an unmet medical need in salvaging infected catheters.
The potential for CTXR shares:
Many investors like development stage biotech stocks because the potential for big gains is possible. CTXR is such a company with a few differentiating factors:
Their products are already fully developed.
The Mino-Lok™ product is patent protected.
Physicians, the FDA, and the clinical trials, are all positive about the Mino-Lok™ product.
Mino-Lok™ could CUT annual healthcare costs by tens of $billions.
Yesterday we indicated the potential market for Mino-Lok™ could be $750M to $1B, then we posed the question; what is that level of potential future revenue worth in the share price, or to a potential acquiring company?
First, let’s review the potential market. Guidance tells us that there are about 500,000 infected CVCs that need intervention annually. CTXR has indicated that Mino-Lok™ treatment will likely cost around $1500 per treatment (an immense savings over the current treatment). That simple math comes out to the $750M estimate. Remember, CTXR will have no competition in this type of treatment.
Analysts consider a price/sales ratio of 1-2 as favorable. Let’s consider the pro forma value of CTXR shares using that P/S ratio. Citius has 8,345,844 shares outstanding (as of 10-17-17 per latest SEC filing).
Revenue of $50M $5.99/share to $11.98/share
Revenue of $100M $11.98/share to $23.96/share
Revenue of $200M $23.96/share to $47.92/share
Revenue of $750M $89.87/share to $179.74/share
We used a conservative P/S ratio of 1-2 above. Companies like AbbVie and Pfizer have P/S ratios over 4.
Now frankly, it could take some time for CTXR to attain revenue levels in the hundreds of millions. But, if/when the Mino-Lok™ product reaches full market potential, the share price appreciation could be 2,100% to 4200% in the price/sales ratio scenario.
Not everyone has the staying power to wait, even for a potential 4,200% gain. But investment firms and big pharma companies with deep pockets do, and we believe those deep pocket investors, as well as savvy individuals, may begin to drive CTXR shares higher in the near term. Every share they can acquire now, will likely be much cheaper than after a Mino-Lok™ FDA approval. Big pharma companies need every $billion in revenues they can buy.
For the reasons above, we believe that Citius shares could show significant gains in the near term, as investors begin to seed their portfolios with CTXR potential, and may show massive gains in the mid-long term as Mino-Lok™ comes to market.
The Team
Original report below
Good day, traders,
Following two flat stocks last week we believe we have found a mover and a biotech with big potential!
In September we talked about Citius Pharmaceuticals, Inc. (NASDAQ: CTXR). Back then, the shares offered an opportunity for a modest 15% gain. Now there is a big FDA catalyst in play.
We have followed CTXR for a while and the news below is an important catalyst.
On October 31st the company announced it has received official notice from the FDA that the investigatory program for Mino-Lok™ is designated “Fast Track”.
A drug that receives Fast Track designation is eligible for the following:
• More frequent meetings with FDA to discuss the drug’s development plan and ensure collection of appropriate data needed to support drug approval;
• More frequent written correspondence from FDA about the design of the clinical trials;
• Priority review to shorten the FDA review process for a new drug from ten months to six months; and,
• Rolling Review, which means Citius can submit completed sections of its New Drug Application (NDA) for review by FDA, rather than waiting until every section of the application is completed before the entire application can be reviewed.
52-week range $2.55 to $14.85 (currently $4.28/share)
Shares outstanding 8.34 million
Shares in float, only 2.81 million
Significant insider ownership
CTXR has two products with blockbuster potential:
Mino-Lok™: The Mino-Lok™ product is an antibiotic lock solution used to treat patients with infected Central Venous Catheters (CVCs). Citius holds the exclusive worldwide license to this patented technology for development and commercialization of Mino-Lok™.
About 7 million CVCs are used annually, and approximately 7% (close to 500,000 incidents) become contaminated leading to serious, life threatening infections called catheter-related blood stream infections (CRBSIs). The standard of care in the management of CRBSI’s consists of removing the infected CVC and replacing it with a new catheter at a different vascular access site. A CVC is basically a long tube inserted through the body and into a major blood vessel to deliver drugs (like chemo).
Mino-Lok™ is intended to salvage the infected CVC, eliminating the need to remove and replace the catheter. This is a recognized unmet medical need. There are currently no alternatives other than the removal and reinsertion of the CVC. Studies show that removal and reinsertion of CVCs have a 15 to 20% (up to 100,000 incidents) complication rate, including pneumothorax, misplacement, and arterial puncture.
The medical community may currently be spending $25 Billion annually treating CRBSI’s.
There are currently no FDA approved therapies to salvage infected CVCs.
Mino-Lok™, in its Phase 2b trial, demonstrated a 100% efficacy rate.
In September, the FDA stated that they recognized there is an unmet medical need in salvaging infected catheters and agreed that an open label, superiority design would address the Company’s concerns and would be acceptable in the phase 3 study plan.
Use this link for detailed information on Mino-Lok™. https://www.citiuspharma.com/minolok/
Hydro-Lido:
Citius is developing a proprietary topical formulation of hydrocortisone (3%) and lidocaine (5%) to provide anti-inflammatory and anesthetic relief to persons suffering from Grade I and II hemorrhoids. Hydro-Lido could become the first FDA-approved product to treat hemorrhoids in the United States.
The company is preparing for a meeting with the FDA to discuss its upcoming phase 2b trials.
The company estimates the markets for Mino-Lok™ and Hydro-Lido at $750 million and $500 million respectively
Who is running the show? Prior to joining Citius, the Executive Chairman, Leonard Mazur, was the co-founder and Vice Chairman of Akrimax Pharmaceuticals, LLC. Akrimax has successfully launched prescription drugs, while acquiring drugs from major pharmaceutical companies.
Myron Holubiak is the President and CEO of Citius. His background includes extensive experience in managing and leading both large and emerging pharmaceutical and life sciences companies. Perhaps the most relevant role, was as the President of Roche Laboratories, Inc., a major research-based pharmaceutical company.
Myron Holubiak has millions of his own money invested in CTXR shares. Leonard Mazur owns 3,337,730 shares (more than the public float). These veterans of Big Pharma know they have a winner and will ultimately cash in.
Conclusion
We believe that Mino-Lok™ could get FDA approval sooner, rather than later, due to the Fast Track designation, and Hydro-Lido further down the road. Estimates for these product’s market potential run from $750 million to $1.25 billion. So, the question becomes, what is that level of potential future revenue worth in the share price, or to a potential acquiring company?
Smart money may want to start acquiring these shares NOW. The closer CTXR gets to FDA approval, and catalysts keep coming, these shares could become less and less affordable.
We believe CTXR shares will show significant gains in the near to mid-term.
We will have updated reports following this initial update on CTXR forthcoming expect a big week.
The Team
$CXTR np update http://mailchi.mp/smallcapstreet/biotech-mover-in-focus-this-week-385177?e=b2474ff63c
https://smallcapnetwork.us16.list-manage.com/
SPYR Makes Mystery Announcement – Time for Takeoff Soon?
November 21, 2017 8:29am PST
Dear SmallCap Network Members,
I haven’t seen anything like this since the Dot Com Boom leading up to the inevitable crash of 2000. I’m referring to the major averages ability to just keep going higher and higher without any sort of major selloff along the way. And, who’s to say there’s going to be an inevitable crash anytime soon?
As long as earnings keep going higher and the economy continues to grow at least at a snail’s pace, which is what it’s been doing for years now, there’s not much out there these days to suggest this eight year bull markets is going to throw in the towel anytime soon.
Even small caps have finally decided to participate with the Russell 2000 picking it up lately. Look at the move the Russell has made over the last several days. If that’s not picking it up, then I have no idea what is. Attribute it to tax reform, or whatever you want, but it is what it is – small caps are roaring again.
It’s about time, because for years small caps have been among the markets’ laggards – with penny stocks taking the brunt of the beating. However, we all know the current administration continues to work hard on the de-regulation front, so that’s always going to help small businesses and small public companies looking to make it.
Less regulation means less red tape for small companies who don’t have the kind of capital to work with that the big boys do. And we can all see just how the markets are interpreting what’s going on right now.
In our own world of small caps, we’ve had some big winners over the last several months in PTOTF, SENS, ABEO, CDNA and CVE. We’ve also had some losers along the way in LTTGF, AKS, EGLT and RBNW. But, the winners have cleary made up for any losers along the way, and then some in a big way.
One stock that just hasn’t done much lately though is SPYR, Inc. (SPYR), the mobile game & app development and publisher. Like we always say though, the best time to pick up the right penny stocks is either when they’re very quiet, or nobody wants them.
Although SPYR seems to be in that category right now, the company did issue another compelling press release this morning suggesting it’s still on the right fundamental road of making a splash in the gaming space.
This morning’s PR was also a little bit of a teaser into what appears to be something potentially big for SPYR’s game portfolio – an announcement that it has signed an important licensing agreement with a major television network that will allow SPYR to publish its first idle tapper game, which is already under development by Reset Studios, using intellectual property (IP) from a popular television series on the network.
SPYR previously announced a publishing agreement with Reset Studios (https://ir.spyr.com/press-releases/detail/196/spyr-signs-multi-game-publishing-deal), a developer that SPYR will soon be launching a new idle tapper game with, utilizing and leveraging Reset’s extensive experience in the role playing game (RPG) genre.
Subject to coordinating publicity with the network, and obtaining the network’s prior approval, SPYR will be identifying the licensed IP and television network as soon as it is contractually permitted to do so.
Mike Turner, SPYR’s VP of Strategic Partnerships states, “Everyone at SPYR is very excited to announce that we have secured a desirable IP license from this very popular TV series for our first game with Reset Studios. The IP is supported by a very broad and active fan base numbering in the tens of millions, who we believe will add to the overall success of the game. With the addition of this game, SPYR brings another quality title and new game genre into our portfolio. The tapper/idle game genre is currently experiencing a lot of success and growth in the gaming industry these days; so, this is exactly the kind of game we should be publishing, and I am excited for fans and gamers to see what we have been working on.”
SPYR anticipates that the game will be in the hands of gamers by the end of this year or early in 2018.
I can honestly say I’m extremely curious to find out who this relationship is with, because it could be a major game changer for the company. Guess we’ll find out soon enough!
Fingers crossed, because there would be nothing more we’d like to see than to see SPYR go rocket ship on its chart here before the end of the year.
Warmest regards,
SmallCap Network
http://www.smallcapnetwork.com
this one is exciting, thank you very much SoGiAm for bringing it up. i just wonder your endless information sources on these potentially lucrative companies – and all other info you provide us.
any thoughts on this particular company? webpages don’t really look like a game developer’s pages and not too much information available about the company either.
yet those idle tapper games seem to have some traction lately and now they have a popular tv series IP for making one?
also no sign of AR games? 😉
$SPYR np – See small cap networks . com… 🙂 Slew of DD there for many months! Never got around to getting in this particular equity. Un able to imagine why. ha also if you + a – between : and ) you get a 🙂 Have some wonder holidays and beyond Chief. btw how is 🙂 $THIN coming along? Best2ALL! 🙂
$Rally On, Traders!
Global Payout Inc. (GOHE) was already primed for action but this morning’s press release definitely helped light the fireworks.
Yeah, management’s bridge-building trip to a Vegas cannabis convention went well. Good news for their “legal green” blockchain platform?
Based on the initial leap from $0.021 to $0.027, I’m thinking a few heads on Wall Street nodded on the news:
GOHE gave those of you who grabbed the open up to 28% so far. The long trend remains intact and the ceiling is now CLEAR for added upside.
The only line in our way this morning was the red 200-day trend. Today cracked that “ceiling” and now it’s time for a lot of sun to shine in!
Stay in the game! Turkey season is coming . . . but the market ain’t shut down YET. Plenty of opportunity left to raise a little more scratch.
Happy, Happy, Happy Trading!
~ Stock Commander
yourstockcommander@gmail.com
To understand the heart and mind of a person, look not at what he has already achieved, but at what he aspires to. ~ Khalil Gibran
$MODN – Comment Link: https://www.stockgumshoe.com/reviews/profits-unlimited/greatest-medical-breakthrough-in-history-and-mampillys-1-stock-for-2018/comment-page-1/#comment-4960888
Author: Brad
Comment:
Today’s extreme fortunes official recommendation by Paul Mampilly is Model N, $MODN. 777 Mariners Island Blvd Ste 300
San Mateo, CA 94404-5089
Phone: (650) 610-4600
Fax: (650) 610-4699
http://www.modeln.com/
Company Profile https://finviz.com/quote.ashx?t=modn
Model N, Inc. is a provider of revenue management solutions for life science and technology companies. The Company’s solutions enable its customers to maximize revenues and reduce revenue compliance risk by transforming their revenue life cycle from a series of tactical, disjointed operations into a strategic end-to-end process. The Company’s solutions include Revenue Enterprise Cloud, Revenue Intelligence Cloud and Revvy Revenue Management. The Company provides solutions that span the organizational and operational boundaries of functions, such as sales, marketing and finance, and serve as a system of record for revenue management processes, including pricing, contracts, rebates, incentives and regulatory compliance. The Company’s application suites are designed to work with enterprise resource planning (ERP) and customer relationship management (CRM) applications. The Company also offers implementation services, managed services, strategic services and customer support.
Comment Link: https://www.stockgumshoe.com/reviews/profits-unlimited/greatest-medical-breakthrough-in-history-and-mampillys-1-stock-for-2018/comment-page-1/#comment-4960947
Author: swing trader > Thankful to you for this and many other fine posts!
Comment:
$MODN has negative EPS and projected to have neg EPS for next few qtrs. You gotta have some patience and faith.
If U use $xyz then easy to locate posts in the future.. 🙂 Best2ALL! 🙂
$BPMX 73.5m shares offering at $.15/share… with 73.5m Series A and B warrants…. only 80m shares before this offering @ShaneBlackman in small position 1/3 at .1181
NO DD has been Done #DYODDNIA
$LPTX in at 6.94 2/3 postion Catalysts in 2018. $LLY increased their position.
Fate Therapeutics, Inc.
Event Reminder
The 29th Annual Piper Jaffray Healthcare Conference
11/28/2017 12:50:00 PM ET
View Event Details http://ir.fatetherapeutics.com//eventdetail.cfm?eventid=186647
$MARK up 12%+
$RIOT up 16%+
$BLKCF
#BlockChain https://www.stockgumshoe.com/2016/07/microblog-ethereum-the-battle-of-the-chains-kraken-etc-eth-more/
New Thread: https://www.stockgumshoe.com/2017/11/microblog-pre-and-after-market-discussion-thread-xyz-or-subject-reqiuired-in-each-post-tia/
$CURR Cure Pharmaceuticals
https://curepharmaceutical.com
Cure is a preeminent developer and manufacturer of the most advanced oral thin film (OTF) on the market today with an industry leading full service cGMP manufacturer. Cure offers the most advanced development and manufacturing of nutraceuticals, OTC products, pharmaceuticals, and veterinary medicants in a patented, proprietary, OTF delivery system. Alongside its stand-alone OTF technology, Cure has developed an array of products in cutting-edge delivery platforms such as, sublingual and transdermal applications. Collectively Cure brings over 90 years of experience formulating and manufacturing nutraceuticals, OTC products, pharmaceuticals, and veterinary medications placing quality and service as our top priorities, thus earning us the trust and respect of customers worldwide.
Bumped into this kind of pharmaceuticals company. I don’t know wether this has been a subject of discussion before and i dare not to present such vague intro in dr. KSS’s tread so i apologize if you’re already familiar with this one.
So basically they have a proprietary drug delivery product, film that dissolves in your mouth, and it can be modified for various kind of drugs, make it taste good, it’s easier for children to consume and so on.
Obviously a need for this kind of drug delivery system is among children, psychiatric patients and animals.
http://client.irwebkit.com/curepharmaceutical/presentations
Company’s presentation doesn’t give out much, but opens up idea a bit further. Maybe this could be an investment idea, maybe it’s just words covered in fancy package. Have to dig deeper and do further DD
My own experience is that unlike presentation says, big pharma isn’t actually most dynamic and open-minded industry for new ideas.
In my own field of expertise i’d be more than happy if i could give a patient strip of film with some opioid in it in order to relief pain before procedures etc instead of pills that one have to try to swallow or even chew or try to find intra venous route when the situation is critical already.
Again, apologies if this company’s presented before.
no position in $CURR
yours, Finn
well this one’s been quite a falling knife lately xD i’m apologise for bad timing #howlowcanyougo
$CURR np -Finventurer,
I like a lot about the #equity. just waiting for the #knife to hit the #Floor 😛 #Beet2YouAlwayz!